Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 1/2008

01-01-2008 | Research Article

Description of pharmacist interventions during physician–pharmacist co-management of hypertension

Authors: Shannon J. Von Muenster, Barry L. Carter, Cynthia A. Weber, Michael E. Ernst, Jessica L. Milchak, Jennifer J. G. Steffensmeier, Yinghui Xu

Published in: International Journal of Clinical Pharmacy | Issue 1/2008

Login to get access

Abstract

Objective The aim of this study is to describe recommendations made by clinical pharmacists when co-managing hypertension with physicians. Setting Two family medicine clinics at a major teaching hospital in the mid-western United States. Method This report details the specific recommendations made by pharmacists during a prospective randomized controlled clinical trial. Patients with uncontrolled hypertension were enrolled in a 9-month intensive pharmacist–physician co-management study. Clinical pharmacists saw patients at baseline, 2, 4, 6, and 8 month visits. Optional visits were allowed between required visits. Main outcome measure For this analysis, pharmacist recommendations were grouped. Physician acceptance of the pharmacists’ recommendations was also evaluated. Results Data from 101 patients were included and analyzed in this study. Changes in drug therapy were recommended 267 times for these 101 patients. Most recommendations for a change in treatment involved adding a new antihypertensive medication (46.4%) or increasing a dose (33.3%). The majority of pharmacist recommendations to modify drug therapy were made at the baseline visit (41.6%), with 76.8% of recommendations made by the 2 month visit. Physicians accepted and implemented 95.9% of the 267 pharmacist recommendations to modify drug therapy. Pharmacists recommended no change in the treatment plan 361 times, most often because the patient’s blood pressure (BP) had achieved the goal. Average BP decreased from 153.1 ± 10.0/84.9 ± 12.0 mmHg (average ± SD) at baseline to 124.2 ± 9.7/74.7 ± 9.6 mmHg (P < 0.001) at the end of 9 months, with 89.1% (P < 0.001) of patients reaching their BP goal. Conclusion Pharmacist recommendations for alterations in drug therapy generally occurred early in the course of the study and were largely to intensify therapy through higher dosages or additional medications. Pharmacist–physician co-management of BP is effective at reducing BP and improving BP control rates.
Literature
1.
go back to reference 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21(6):1011–53. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21(6):1011–53.
3.
go back to reference Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003;42(6):1206–52.PubMedCrossRef Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003;42(6):1206–52.PubMedCrossRef
4.
go back to reference Petrella RJ, Campbell NR. Awareness and misconception of hypertension in Canada: results of a national survey. Can J Cardiol 2005;21(7):589–93.PubMed Petrella RJ, Campbell NR. Awareness and misconception of hypertension in Canada: results of a national survey. Can J Cardiol 2005;21(7):589–93.PubMed
6.
go back to reference Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004. Hypertension 2007;49(1):69–75.PubMedCrossRef Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004. Hypertension 2007;49(1):69–75.PubMedCrossRef
7.
go back to reference Coca A, Aranda P, Bertomeu V, Bonet A, Esmatjes E, Guillen F, et al. Strategies for effective control of arterial hypertension in Spain. Consensus document. Rev Clin Esp 2006;206(10):510–4.PubMedCrossRef Coca A, Aranda P, Bertomeu V, Bonet A, Esmatjes E, Guillen F, et al. Strategies for effective control of arterial hypertension in Spain. Consensus document. Rev Clin Esp 2006;206(10):510–4.PubMedCrossRef
8.
go back to reference Black HR, Elliott WJ, Neaton JD, Grandits G, Grambsch P, Grimm RH Jr, et al. Baseline characteristics and early blood pressure control in the CONVINCE trial. Hypertension 2001;37(1):12–8.PubMed Black HR, Elliott WJ, Neaton JD, Grandits G, Grambsch P, Grimm RH Jr, et al. Baseline characteristics and early blood pressure control in the CONVINCE trial. Hypertension 2001;37(1):12–8.PubMed
9.
go back to reference Bond CA, Monson R. Sustained improvement in drug documentation, compliance, and disease control. A four-year analysis of an ambulatory care model. Arch Intern Med 1984;144(6):1159–62.PubMedCrossRef Bond CA, Monson R. Sustained improvement in drug documentation, compliance, and disease control. A four-year analysis of an ambulatory care model. Arch Intern Med 1984;144(6):1159–62.PubMedCrossRef
10.
go back to reference Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351(9118):1755–62.PubMedCrossRef Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351(9118):1755–62.PubMedCrossRef
11.
go back to reference Grimm RH Jr, Margolis KL, Papademetriou VV, Cushman WC, Ford CE, Bettencourt J, et al. Baseline characteristics of participants in the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). Hypertension 2001;37(1):19–27.PubMed Grimm RH Jr, Margolis KL, Papademetriou VV, Cushman WC, Ford CE, Bettencourt J, et al. Baseline characteristics of participants in the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). Hypertension 2001;37(1):19–27.PubMed
12.
go back to reference Carter BL, Zillich AJ, Elliott WJ. How pharmacists can assist physicians with controlling blood pressure. J Clin Hypertens 2003;5(1):31–7.CrossRef Carter BL, Zillich AJ, Elliott WJ. How pharmacists can assist physicians with controlling blood pressure. J Clin Hypertens 2003;5(1):31–7.CrossRef
13.
go back to reference Miller NH, Hill M, Kottke T, Ockene IS. The multilevel compliance challenge: recommendations for a call to action. A statement for healthcare professionals. Circulation 1997;95(4):1085–90.PubMed Miller NH, Hill M, Kottke T, Ockene IS. The multilevel compliance challenge: recommendations for a call to action. A statement for healthcare professionals. Circulation 1997;95(4):1085–90.PubMed
14.
go back to reference Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med 2001;345(7):479–86.PubMedCrossRef Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med 2001;345(7):479–86.PubMedCrossRef
15.
go back to reference Berlowitz DR, Ash AS, Hickey EC, Friedman RH, Glickman M, Kader B, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998;339(27):1957–63.PubMedCrossRef Berlowitz DR, Ash AS, Hickey EC, Friedman RH, Glickman M, Kader B, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998;339(27):1957–63.PubMedCrossRef
16.
go back to reference Oliveria SA, Lapuerta P, McCarthy BD, L’Italien GJ, Berlowitz DR, Asch SM. Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med 2002;162(4):413–20.PubMedCrossRef Oliveria SA, Lapuerta P, McCarthy BD, L’Italien GJ, Berlowitz DR, Asch SM. Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med 2002;162(4):413–20.PubMedCrossRef
17.
go back to reference Monson R, Bond CA, Schuna A. Role of the clinical pharmacist in improving drug therapy. Clinical pharmacists in outpatient therapy. Arch Intern Med 1981;141(11):1441–4.PubMedCrossRef Monson R, Bond CA, Schuna A. Role of the clinical pharmacist in improving drug therapy. Clinical pharmacists in outpatient therapy. Arch Intern Med 1981;141(11):1441–4.PubMedCrossRef
18.
go back to reference Bogden PE, Abbott RD, Williamson P, Onopa JK, Koontz LM. Comparing standard care with a physician and pharmacist team approach for uncontrolled hypertension. J Gen Intern Med 1998;13(11):740–5.PubMedCrossRef Bogden PE, Abbott RD, Williamson P, Onopa JK, Koontz LM. Comparing standard care with a physician and pharmacist team approach for uncontrolled hypertension. J Gen Intern Med 1998;13(11):740–5.PubMedCrossRef
19.
go back to reference Borenstein JE, Graber G, Saltiel E, Wallace J, Ryu S, Archi J, et al. Physician–pharmacist comanagement of hypertension: a randomized, comparative trial. Pharmacotherapy 2003;23(2):209–16.PubMedCrossRef Borenstein JE, Graber G, Saltiel E, Wallace J, Ryu S, Archi J, et al. Physician–pharmacist comanagement of hypertension: a randomized, comparative trial. Pharmacotherapy 2003;23(2):209–16.PubMedCrossRef
20.
go back to reference Erickson SR, Slaughter R, Halapy H. Pharmacists’ ability to influence outcomes of hypertension therapy. Pharmacotherapy 1997;17(1):140–7.PubMed Erickson SR, Slaughter R, Halapy H. Pharmacists’ ability to influence outcomes of hypertension therapy. Pharmacotherapy 1997;17(1):140–7.PubMed
21.
go back to reference Forstrom MJ, Ried LD, Stergachis AS, Corliss DA. Effect of a clinical pharmacist program on the cost of hypertension treatment in an HMO family practice clinic. DICP 1990;24(3):304–9.PubMed Forstrom MJ, Ried LD, Stergachis AS, Corliss DA. Effect of a clinical pharmacist program on the cost of hypertension treatment in an HMO family practice clinic. DICP 1990;24(3):304–9.PubMed
22.
go back to reference Hawkins DW, Fiedler FP, Douglas HL, Eschbach RC. Evaluation of a clinical pharmacist in caring for hypertensive and diabetic patients. Am J Hosp Pharm 1979;36(10):1321–5.PubMed Hawkins DW, Fiedler FP, Douglas HL, Eschbach RC. Evaluation of a clinical pharmacist in caring for hypertensive and diabetic patients. Am J Hosp Pharm 1979;36(10):1321–5.PubMed
23.
go back to reference Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA 2006. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA 2006.
24.
go back to reference McGhan WF, Stimmel GL, Hall TG, Gilman TM. A comparison of pharmacists and physicians on the quality of prescribing for ambulatory hypertensive patients. Med Care 1983;21(4):435–44.PubMedCrossRef McGhan WF, Stimmel GL, Hall TG, Gilman TM. A comparison of pharmacists and physicians on the quality of prescribing for ambulatory hypertensive patients. Med Care 1983;21(4):435–44.PubMedCrossRef
25.
go back to reference McKenney JM. Pharmacy management of hypertensive patients. J Am Pharm Assoc 1974;14(4):190–5.PubMed McKenney JM. Pharmacy management of hypertensive patients. J Am Pharm Assoc 1974;14(4):190–5.PubMed
26.
go back to reference McKenney JM, Slining JM, Henderson HR, Devins D, Barr M. The effect of clinical pharmacy services on patients with essential hypertension. Circulation 1973;48(5):1104–11.PubMed McKenney JM, Slining JM, Henderson HR, Devins D, Barr M. The effect of clinical pharmacy services on patients with essential hypertension. Circulation 1973;48(5):1104–11.PubMed
27.
go back to reference Mehos BM, Saseen JJ, MacLaughlin EJ. Effect of pharmacist intervention and initiation of home blood pressure monitoring in patients with uncontrolled hypertension. Pharmacotherapy 2000;20(11):1384–9.PubMedCrossRef Mehos BM, Saseen JJ, MacLaughlin EJ. Effect of pharmacist intervention and initiation of home blood pressure monitoring in patients with uncontrolled hypertension. Pharmacotherapy 2000;20(11):1384–9.PubMedCrossRef
28.
go back to reference Park JJ, Kelly P, Carter BL, Burgess PP. Comprehensive pharmaceutical care in the chain (pharmacy) setting. J Am Pharm Assoc 1996;NS36(7):443–51. Park JJ, Kelly P, Carter BL, Burgess PP. Comprehensive pharmaceutical care in the chain (pharmacy) setting. J Am Pharm Assoc 1996;NS36(7):443–51.
29.
go back to reference Vivian EM. Improving blood pressure control in a pharmacist-managed hypertension clinic. Pharmacotherapy 2002;22(12):1533–40.PubMedCrossRef Vivian EM. Improving blood pressure control in a pharmacist-managed hypertension clinic. Pharmacotherapy 2002;22(12):1533–40.PubMedCrossRef
30.
go back to reference Walsh JM, McDonald KM, Shojania KG, Sundaram V, Nayak S, Lewis R, et al. Quality improvement strategies for hypertension management: a systematic review. Med Care 2006;44(7):646–57.PubMedCrossRef Walsh JM, McDonald KM, Shojania KG, Sundaram V, Nayak S, Lewis R, et al. Quality improvement strategies for hypertension management: a systematic review. Med Care 2006;44(7):646–57.PubMedCrossRef
31.
go back to reference Zillich AJ, Sutherland JM, Kumbera PA, Carter BL. Hypertension outcomes through blood pressure monitoring and evaluation by pharmacists (HOME study). J Gen Intern Med 2005;20(12):1091–6.PubMedCrossRef Zillich AJ, Sutherland JM, Kumbera PA, Carter BL. Hypertension outcomes through blood pressure monitoring and evaluation by pharmacists (HOME study). J Gen Intern Med 2005;20(12):1091–6.PubMedCrossRef
32.
go back to reference Carter BL, Barnette DJ, Chrischilles E, Mazzotti GJ, Asali ZJ. Evaluation of hypertensive patients after care provided by community pharmacists in a rural setting. Pharmacotherapy 1997;17(6):1274–85.PubMed Carter BL, Barnette DJ, Chrischilles E, Mazzotti GJ, Asali ZJ. Evaluation of hypertensive patients after care provided by community pharmacists in a rural setting. Pharmacotherapy 1997;17(6):1274–85.PubMed
33.
go back to reference Carter BL, Helling DK. Ambulatory care pharmacy services: has the agenda changed? Ann Pharmacother 2000;34(6):772–87.PubMedCrossRef Carter BL, Helling DK. Ambulatory care pharmacy services: has the agenda changed? Ann Pharmacother 2000;34(6):772–87.PubMedCrossRef
34.
go back to reference Brown DJ, Helling DK, Jones ME. Evaluation of clinical pharmacist consultations in a family practice office. Am J Hosp Pharm 1979;36(7):912–5.PubMed Brown DJ, Helling DK, Jones ME. Evaluation of clinical pharmacist consultations in a family practice office. Am J Hosp Pharm 1979;36(7):912–5.PubMed
35.
go back to reference Chrischilles EA, Carter BL, Lund BC, Rubenstein LM, Chen-Hardee SS, Voelker MD, et al. Evaluation of the Iowa Medicaid pharmaceutical case management program. J Am Pharm Assoc (Wash DC) 2004;44(3):337–49. Chrischilles EA, Carter BL, Lund BC, Rubenstein LM, Chen-Hardee SS, Voelker MD, et al. Evaluation of the Iowa Medicaid pharmaceutical case management program. J Am Pharm Assoc (Wash DC) 2004;44(3):337–49.
36.
go back to reference Haxby DG, Weart CW, Goodman BW Jr. Family practice physicians’ perceptions of the usefulness of drug therapy recommendations from clinical pharmacists. Am J Hosp Pharm 1988;45(4):824–7.PubMed Haxby DG, Weart CW, Goodman BW Jr. Family practice physicians’ perceptions of the usefulness of drug therapy recommendations from clinical pharmacists. Am J Hosp Pharm 1988;45(4):824–7.PubMed
37.
go back to reference Carter BL, Bergus GR, Dawson JD, Farris KB, Doucette WR, Chrischilles EA, et al. A cluster-randomized trial to evaluate physician/pharmacist collaboration to improve blood pressure control. J Clin Hypertens (Submitted June 2007). Carter BL, Bergus GR, Dawson JD, Farris KB, Doucette WR, Chrischilles EA, et al. A cluster-randomized trial to evaluate physician/pharmacist collaboration to improve blood pressure control. J Clin Hypertens (Submitted June 2007).
38.
go back to reference Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002;288(19):2421–31.PubMedCrossRef Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002;288(19):2421–31.PubMedCrossRef
39.
go back to reference Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, et al. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension 2005;2005(45):142–61. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, et al. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension 2005;2005(45):142–61.
40.
go back to reference Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363(9426):2022–31.PubMedCrossRef Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363(9426):2022–31.PubMedCrossRef
Metadata
Title
Description of pharmacist interventions during physician–pharmacist co-management of hypertension
Authors
Shannon J. Von Muenster
Barry L. Carter
Cynthia A. Weber
Michael E. Ernst
Jessica L. Milchak
Jennifer J. G. Steffensmeier
Yinghui Xu
Publication date
01-01-2008
Publisher
Springer Netherlands
Published in
International Journal of Clinical Pharmacy / Issue 1/2008
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-007-9155-6

Other articles of this Issue 1/2008

International Journal of Clinical Pharmacy 1/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.